Oliver W. Press
M.D., University of Washington, Medical Scientist Training Program, 1979.
Ph.D., University of Washington, Biological Structure, 1977.
B.S., Stanford University, Biology, 1973.
My program is devoted to the investigation of novel treatments for hematologic malignancies including non-Hodgkin's lymphoma and acute and chronic leukemias. We conduct basic laboratory investigations using leukemia and lymphoma cell lines and mouse xenograft models as well as human clinical trials. Agents currently under investigation include monoclonal antibodies, radioimmunoconjugates, immunotoxins, chemotherapeutic agents, and genetically modified cytotoxic T lymphocytes. In the clinical arena, we are continuing our successful program of high dose radioimmunotherapy with stem cell transplantation for B cell lymphomas and have trials planned investigating pretargeted radioimmunotherapy and gene therapy using adoptively transferred cytotoxic T lymphocytes bearing chimeric anti-CD20 receptors.
Postgraduate Training in Internal Medicine:
Fellow in Oncology, University of Washington/Fred Hutchinson Cancer Research Center, 1983-1986
Chief Residency, University of Washington Medical Center, Seattle, 1982-1983
Residency, Massachusetts General Hospital, Boston, 1980-1982
Internship, Massachusetts General Hospital, Boston, 1979-1980
Medical Oncology Certification (A.B.I.M.), November, 1985
American Board of Internal Medicine, Sept. 15, 1982
National Board of Medical Examiners, July 1, 1980
State of Washington, #20170 (8/6/82).
Associate Editor, Journal of the National Cancer Institute, 1991-1995
Managing Editor, annals of Hematology, 1998-2001
Editor, Blood, 2001-present
Editor, Journal of Therapeutic Immunology, 1995-1999
Editor, Advances in Leukemia/Lymphoma
Editor, Tumor Targeting
Editor, Cancer Biotherapy and Radiopharmaceuticals
Editor, Cytokines, Cellular & Molecular Therapy
Reviewer, Cancer Research/Clinical Cancer Research/Journal of Immunology/Journal of Clinical Oncology/Blood/Chest.
American Association for Cancer Research
American Association of Physicians
American Federation for Clinical Research, Councilor for Washington
American Medical Association
American Society for Clinical Investigation
American Society for Clinical Oncology
American Society for Gene Therapy
American Society of Hematology
Southwest Oncology Group
Honors and Awards
2009, Co-Chair, Lymphoma Steering Committee, National Cancer Institute
2007, Ellen Glesby Cohen Leadership Award, Lymphoma Research Foundation
2005, Chairman, Scientific Advisory Board, Lymphoma Research Foundation
2002, Selected as one of Seattle's 'Best Doctors', Seattle Magazine
2001-2003, Selected as one of 'America's Top Doctors',
2000, Election to the American Association of Physicians ('Old Turks'),
1998, CRS-Cygnus Award for Outstanding Work in Drug Delivery,
1996, Election to the American Society for Clinical Investigation ('Young Turks'),
1993-1995, Recipient of the first Boeing Corporate Medical Research Award,
1988-1989, Elsa Pardee Award for Cancer Research,
1987-1992, First Independent Research and Training Award from the National Institutes of Health,
1985-1986, Young Investigator Award from the American Society for Clinical Oncology,
1985-1988, Clinical Oncology Career Development Award from the American Cancer Society,
1979, PhD Thesis Honors, University of Washington
1979, Medical Auxiliary MD, PhD Award,
1979, Graduation with 'Highest Honors' from University of Washington School of Medicine,
1979, Robert S. Evans Award,
1979, John J. Bonica Prize in Anesthesiology,
1979, Lamport Biomedical Research Prize,
1979, Seattle Academy of Internal Medicine Prize,
1978, Scholarship from International College of Surgeons,
1976, Alpha Omega Alpha, Honorary Medical Fraternity (elected as 3rd year student in Spring, 1976),
1973, Phi Beta Kappa, Stanford University
1973, Departmental Honors and Departmental Distinction in Biology, Stanford University
1970-1973, George E. Gamble Honors Scholarship, Stanford University
2005-2009, Clinical Research in Hematology and Hematologic Malignancies, Seattle Cancer Care Alliance
1996-2007, Biological Structure, University of Washington, Biological Structure
1993-2000, Acting Program Director, University of Washington Medical Center, High-Dose Chemotherapy Unit
1991-1996, Associate Member, Fred Hutchinson Cancer Research Center
1991-2006, Associate Director, University of Washington, Medical Scientist Training Program
1991-1996, Associate Professor in Medicine, University of Washington
1991-2006, Associate Director, Medical Scientist Training Program, University of Washington, School of Medicine
1988-1991, Adjunct Assistant Professor of Biological Structure, University of Washington
1987-1991, Assistant Professor in Medicine, University of Washington
1986-1991, Assistant Member, Fred Hutchinson Cancer Research Center
1983-1986, Senior Fellow, Fred Hutchinson Cancer Research Center
1982-1986, Acting Instructor in Medicine, University of Washington
1979-1982, Clinical Fellow in Medicine, Harvard University, Medical School
Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT C. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(13):1662-8.. 2013.
Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin Lymphoma: SWOG S0016.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(3):314-20.. 2013.
Selection of first-line therapy for advanced follicular lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(12):1496-8.. 2013.
131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's lymphoma: radiation dose to the testes.. Nuclear medicine communications. 33(12):1225-31.. 2012.
Intracellular Delivery and Trafficking Dynamics of a Lymphoma-Targeting Antibody-Polymer Conjugate.. Molecular pharmaceutics.. 2012.
Depletion of Tregs for adoptive T-cell therapy using CD44 and CD137 as selection markers.. Immunotherapy. 4(5):483-5.. 2012.
Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 17(10):1537-45.. 2011.
Non-Hodgkin's lymphomas.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(5):484-560.. 2011.
Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 52(6):896-900.. 2011.
Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report.. Leukemia & lymphoma. 52(7):1188-99.. 2011.
Mantle cell lymphoma: report of the 2010 Mantle Cell Lymphoma Consortium Workshop.. Leukemia & lymphoma. 52(1):24-33.. 2011.
Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. 17(23):7373-82.. 2011.
Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(22):3023-9.. 2011.
Anti-CD22 Antibody Targeting of pH-responsive Micelles Enhances Small Interfering RNA Delivery and Gene Silencing in Lymphoma Cells.. Molecular therapy : the journal of the American Society of Gene Therapy. 19(8):1529-37.. 2011.
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas.. Journal of the National Comprehensive Cancer Network : JNCCN. 8(3):288-334.. 2010.
Recent advances in novel radioimmunotherapeutic approaches for allogeneic hematopoietic cell transplantation.. Current opinion in oncology. 22(2):143-9.. 2010.